$0.47
5.23% today
Nasdaq, Nov 20, 08:47 pm CET
ISIN
US00972G1085
Symbol
AKTX

Akari Therapeutics Plc Sponsored ADR Stock price

$0.50
-0.27 35.23% 1M
-0.76 60.52% 6M
-0.72 59.12% YTD
-1.07 68.24% 1Y
-11.10 95.70% 3Y
-31.30 98.43% 5Y
-387.50 99.87% 10Y
-3,999.50 99.99% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
-0.03 6.01%
ISIN
US00972G1085
Symbol
AKTX
Industry

Key metrics

Basic
Market capitalization
$17.3m
Enterprise Value
$16.2m
Net debt
positive
Cash
$2.7m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
0.7
Financial Health
Equity Ratio
44.0%
Return on Equity
-89.0%
ROCE
-37.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-12.8m | -
EBIT
$-12.8m | $-14.7m
Net Income
$-12.3m | -
Free Cash Flow
$-9.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
54.9% | -
EBIT
54.9% | 11.8%
Net Income
47.0% | -
Free Cash Flow
42.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
-
Short interest
0.7%
Employees
9
Rev per Employee
$0.0
Show more

Is Akari Therapeutics Plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Akari Therapeutics Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Akari Therapeutics Plc Sponsored ADR forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Akari Therapeutics Plc Sponsored ADR forecast:

Buy
89%
Hold
11%

Financial data from Akari Therapeutics Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.92 9.92
43% 43%
-
- Research and Development Expense 2.87 2.87
74% 74%
-
-13 -13
55% 55%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
55% 55%
-
Net Profit -12 -12
47% 47%
-

In millions USD.

Don't miss a Thing! We will send you all news about Akari Therapeutics Plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akari Therapeutics Plc Sponsored ADR Stock News

Neutral
Seeking Alpha
2 days ago
Akari Therapeutics, Plc ( AKTX ) Shareholder/Analyst Call November 18, 2025 11:00 AM EST Company Participants Abizer Gaslightwala - CEO, President & Director Satyajit Mitra - Executive Director & Head of Oncology Conference Call Participants Jenene Thomas Presentation Jenene Thomas Okay. We are ready to get started, and welcome, everyone, to the Akari Therapeutics Corporate Update Webcast.
Neutral
GlobeNewsWire
2 days ago
More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track record scaling companies from preclinical to clinical milestones More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track re...
Neutral
GlobeNewsWire
10 days ago
Data presented at the 40 th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor immunity through multiple mechanisms Treatment with a Trastuzumab-PH1 ADC monotherapy drove macrophages to polarize into an anti-tumor/inflammatory state and caused expansion of...
More Akari Therapeutics Plc Sponsored ADR News

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Abizer Gaslightwala
Employees 9
Founded 2004
Website www.akaritx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today